We are excited to once again assemble many of the leading clinicians and scientists from around the world for the 8th Advances Against Aspergillosis conference, to take place in Lisbon, Portugal from 1st to 3rd February 2018. This conference has now clearly established itself as the premier forum for detailed and dedicated discussion of all aspects of Aspergillus infection and research, and previously published proceedings have been very well-received.
The Aspergillus field continues in a state of rapid advancement, including the publication of numerous post-genomic papers and substantial advances in translational, immunologic, epidemiologic and diagnostic research. The launch of several antifungals in the last few years and anticipated clinical trials of newer compounds with novel mechanisms of action is an exciting time for mycology. Pan-azole, and echinocandin resistance has emerged and requires unique approaches, and combination therapy remains an important area of interest. Greatly increased awareness of allergic aspergillosis has opened new opportunities for both antifungal agents and immunotherapies. New molecular strategies for diagnosis continue to make progress, and recent guidelines offer increased diagnostic insight. There is a continuing high death toll from invasive aspergillosis, including patient groups not usually associated with this opportunistic infection. This meeting is another chance to gather the world’s aspergillosis experts in one venue. A fundamental tenet of this colloquium continues to be to engender collaborative relationships amongst clinicians, scientists, and industry to further advance the field.